- 91% of brands have moved at least a part of their digital marketing operations in-house. (Source: Search Engine Journal)
- Cost efficiency, greater control, and increased transparency are amongst the biggest reasons for in-housing.
- 56% of respondents say a lack of existing talent and skills to build a competent in-house team in the biggest obstacle.
- 41 of Pfizer’s drugs have been picked for a price hike on January 15, averaging 5%.
- Pfizer noted Friday that the increases will be offset by higher rebates and discounts offered to insurance companies and pharmacy benefit managers.
- Pfizer had the highest profit total ($4.1 billion) of any publicly traded health care company in the third quarter.
- Pharma companies don’t really care about patients despite all their hubris.
- PhRMA has already spent $21 million on lobbying this year — a sum that puts it on course to smash its previous annual lobbying records.
- Pharmaceutical companies have been top performers in the healthcare sector in an era of aging populations, rising health care costs, and the ongoing development of new and extremely profitable medicines.
- Research shows that 78 percent of patents approved by the U.S. Food and Drug Administration correspond to medications already on the market.
- Large pharma companies spend more on share buybacks to boost share prices (and stock options — the main way that executives get paid) than on research and development.
- President Donald Trump in May said that drugmakers would soon announce “massive” price cuts but they aren’t in the loop.
- Bayer raised the price of two cancer drugs by hundreds of dollars in May and Novartis followed by boosting four pricey treatments in June. [inlinetweet prefix=”” tweeter=”” suffix=””]Pfizer, one of the largest U.S. pharma companies, announced increases on more than 41 products this week.[/inlinetweet]
- [inlinetweet prefix=”” tweeter=”” suffix=””]A Wells Fargo report found 104 price increases in June and the first two days of July[/inlinetweet], with an average jump of 31.5 percent and a median increase of 9.4 percent. That followed 48 increases in May.
KEY TAKEAWAY: Mr Trump’s plan to curtail drug prices was long on slogans and short on substance. To understand who the winners were just follow the money via Wall Street.
KEY TAKEAWAY: The pharma industry’s top trade group on Tuesday launched a new series of ads as part of its drug pricing campaign aimed at blaming cost increases on insurers and pharmacy benefit managers. However, it’s trying to bail water from a sinking ship. Continue reading